NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• NewAmsterdam Pharma Company N.V. has received an average recommendation of "Moderate Buy" from nine brokerages, with one hold and eight buy ratings, and a 12-month price target averaging $42.00.
• The company's shares recently increased by 8.4%, opening at $28.50, with a market cap of $3.21 billion and a 52-week price range between $14.06 and $28.61.
• In its latest quarterly earnings report, NewAmsterdam Pharma posted a loss of ($0.15) earnings per share, outperforming analysts' expectations of ($0.52), with revenue significantly above consensus at $19.15 million.

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) have earned an average recommendation of "Moderate Buy" from the nine brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $42.00.

Several analysts have recently commented on the stock. Cantor Fitzgerald assumed coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, June 4th. They set an "overweight" rating and a $42.00 price objective on the stock. Stifel Nicolaus initiated coverage on NewAmsterdam Pharma in a report on Tuesday, June 10th. They set a "buy" rating and a $44.00 price target on the stock. Wells Fargo & Company started coverage on NewAmsterdam Pharma in a research note on Monday, August 25th. They issued an "overweight" rating and a $45.00 price objective for the company. Royal Bank Of Canada lifted their target price on NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an "outperform" rating in a research note on Thursday, August 7th. Finally, Citigroup began coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 17th. They set a "buy" rating and a $42.00 price objective for the company.

NewAmsterdam Pharma Stock Up 8.4%

Shares of NAMS opened at $28.50 on Friday. The business has a 50-day simple moving average of $24.64 and a two-hundred day simple moving average of $21.10. NewAmsterdam Pharma has a 52 week low of $14.06 and a 52 week high of $28.61. The stock has a market cap of $3.21 billion, a price-to-earnings ratio of -17.59 and a beta of -0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.37. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.The company had revenue of $19.15 million during the quarter, compared to the consensus estimate of $1.44 million. On average, equities analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, insider Johannes Jacob Piete Kastelein sold 50,000 shares of NewAmsterdam Pharma stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $24.29, for a total value of $1,214,500.00. Following the sale, the insider directly owned 119,302 shares in the company, valued at approximately $2,897,845.58. The trade was a 29.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $25.83, for a total value of $3,874,500.00. Following the completion of the sale, the chief accounting officer directly owned 15,000 shares in the company, valued at $387,450. This trade represents a 90.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders purchased 2,391 shares of company stock valued at $58,424 and sold 324,954 shares valued at $7,844,906. Corporate insiders own 20.84% of the company's stock.

Institutional Trading of NewAmsterdam Pharma

A number of large investors have recently made changes to their positions in NAMS. Mirae Asset Global Investments Co. Ltd. grew its position in NewAmsterdam Pharma by 19.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock worth $80,000 after acquiring an additional 596 shares in the last quarter. Northern Trust Corp purchased a new position in shares of NewAmsterdam Pharma in the 4th quarter worth approximately $556,000. PTM Wealth Management LLC bought a new position in shares of NewAmsterdam Pharma during the 2nd quarter valued at approximately $256,000. Arizona State Retirement System purchased a new stake in NewAmsterdam Pharma during the 1st quarter valued at $215,000. Finally, California State Teachers Retirement System lifted its position in NewAmsterdam Pharma by 23.5% in the fourth quarter. California State Teachers Retirement System now owns 19,404 shares of the company's stock worth $499,000 after buying an additional 3,694 shares during the last quarter. 89.89% of the stock is currently owned by institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.